Testing

In February 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Chantell Canfield • March 3, 2022

CPT Code updates posted to mayocliniclabs.com during the month of February

By Michael Hutchison • March 2, 2022

Audrey Schuetz, M.D., provides a detailed overview of Mayo Clinic Laboratories’ new culture-based extended spectrum beta lactamase (ESBL) testing. Used to screen for the presence of multi-drug resistant gram-negative bacteria in donor stool intended for fecal microbiota transplantation, the screening test is performed on stool or swab samples taken from around the anus to detect potentially harmful ESBL bacteria that could jeopardize the outcomes of fecal microbiota transplants -- especially in patients who carry the bacteria in their gut without getting sick.

By Barbara J. Toman • March 1, 2022

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay can help confirm the most-severe stiff-person phenotype — known as PERM — which is associated with potential cancers.

By Barbara J. Toman • February 22, 2022

In January 2022, Mayo Clinic Laboratories announced twenty five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Chantell Canfield • February 3, 2022

CPT code updates posted to mayocliniclabs.com during the month of January.

By Michael Hutchison • February 2, 2022

Joseph Yao, M.D., explains how Mayo Clinic Laboratories’ SARS four-target test for viral respiratory disease can enhance patient care. The test detects RNA from SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus, or RSV. RSV — which poses significant risks for infants and patients with underlying health conditions — can be treated if diagnosed early.

By Samantha Rossi • January 18, 2022

December 2021, Mayo Clinic Laboratories announced thirty new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Chantell Canfield • January 6, 2022

CPT code updates posted to mayocliniclabs.com during the month of December.

By MCL Education • January 3, 2022

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.

By Samantha Rossi • December 28, 2021

The following list includes updates posted to mayocliniclabs.com during the month of November.

By MCL Education • December 2, 2021

Michelle Kluge, M.S., CGC, explains how Mayo Clinic Laboratories’ CYPZ assay provides accurate testing for congenital adrenal hyperplasia. Using an in-depth methodology that incorporates Sanger sequencing, MCL can provide clear answers for carriers and individuals clinically affected by the most common form of CAH.

By Samantha Rossi • November 23, 2021

Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.

By Samantha Rossi • November 16, 2021